Renaudineau Y, Chauveau D, Faguer S, Huart A, Ribes D, Pugnet G et al. Urinary soluble CD163 is useful as "liquid biopsy" marker in lupus nephritis at both diagnosis and follow-up to predict impending flares. J Transl Autoimmun. 2024 Jun 20;9:100244. PMID: 39021518;
Rojas-Rivera JE, García-Carro C, Ávila et al. Diagnosis and treatment of lupus nephritis: a summary of the Consensus Document of the Spanish Group for the Study of Glomerular Diseases (GLOSEN). Clin Kidney J. 2023 Mar 22;16(9):1384-1402.
Palsson R, Short SAP, Kibbelaar ZA, Amodu A, Stillman IE, Rennke HG, et al. Bleeding Complications After Percutaneous Native Kidney Biopsy: Results From the Boston Kidney Biopsy Cohort. Kidney Int Rep. 2020 Mar 4;5(4):511-518. PMID: 32274455.
Alduraibi FK, Tsokos GC. Lupus Nephritis Biomarkers: A Critical Review. Int J Mol Sci. 2024 Jan 9;25(2):805. PMID: 38255879.
Omer MH, Shafqat A, Ahmad O, Nadri J, AlKattan K, Yaqinuddin A. Urinary Biomarkers for Lupus Nephritis: A Systems Biology Approach. J Clin Med. 2024 Apr 18;13(8):2339. PMID: 38673612.
Kwant LE, Vegting Y, Tsang-A-Sjoe MWP, Kwakernaak AJ, Vogt L, Voskuyl AE, van Vollenhoven RF, et al. Macrophages in Lupus Nephritis: Exploring a potential new therapeutic avenue. Autoimmun Rev. 2022 Dec;21(12):103211. PMID: 36252930.
Yunna C, Mengru H, Lei W, Weidong C. Macrophage M1/M2 polarization. Eur J Pharmacol. 2020 Jun 15;877:173090. PMID: 32234529.
Møller HJ. Soluble CD163. Scand J Clin Lab Invest. 2012 Feb;72(1):1-13. PMID: 22060747.
Chen Z, Wang GS, Wang GH, et al. Anti-C1q antibody is a valuable biological marker for prediction of renal pathological characteristics in lupus nephritis. Clin Rheumatol. 2012 Sep;31(9):1323-9. PMID: 22696012.
Olson LB, Hunter NI, Rempel RE et al. Targeting DAMPs with nucleic acid scavengers to treat lupus. Transl Res. 2022 Jul;245:30-40. PMID: 35245691
Hedberg A, Mortensen ES, Rekvig OP. Chromatin as a target antigen in human and murine lupus nephritis. Arthritis Res Ther. 2011 Apr 18;13(2):214. PMID: 21542875.
Levey AS, Coresh J, Tighiouart H, et al. Measured and estimated glomerular filtration rate: current status and future directions. Nat Rev Nephrol. 2020 Jan;16(1):51-64. PMID: 31527790.
Moran SM, Scott J, Clarkson MR et al. The Clinical Application of Urine Soluble CD163 in ANCA-Associated Vasculitis. J Am Soc Nephrol. 2021 Nov;32(11):2920-2932. PMID: 34518279.
Mejia-Vilet JM, Zhang XL, Cruz C et al. Urinary Soluble CD163: a Novel Noninvasive Biomarker of Activity for Lupus Nephritis. J Am Soc Nephrol. 2020 Jun;31(6):1335-1347. PMID: 32300067.
Zhang T, Li H, Vanarsa K et al. Association of Urine sCD163 With Proliferative Lupus Nephritis, Fibrinoid Necrosis, Cellular Crescents and Intrarenal M2 Macrophages. Front Immunol. 2020 Apr 15;11:671. PMID: 32351512.
David C, Divard G, Abbas R et al. Soluble CD163 is a biomarker for accelerated atherosclerosis in systemic lupus erythematosus patients at apparent low risk for cardiovascular disease. Scand J Rheumatol. 2020 Jan;49(1):33-37. PMID: 31161842.
Nishino A, Katsumata Y, Kawasumi H, et al. Usefulness of soluble CD163 as a biomarker for macrophage activation syndrome associated with systemic lupus erythematosus. Lupus. 2019 Jul;28(8):986-994. PMID: 31246559.
Nakayama W, Jinnin M, Makino K, et al. CD163 expression is increased in the involved skin and sera of patients with systemic lupus erythematosus. Eur J Dermatol. 2012 Jul-Aug;22(4):512-7. PMID: 22576016.
Yang G, Guo N, Yin J, et al. Elevated soluble CD163 predicts renal function deterioration in lupus nephritis: a cohort study in Eastern China. J Int Med Res. 2021 Nov;49(11):3000605211049963. PMID: 34755559.
Tan G, Baby B, Zhou Y, et al. Emerging Molecular Markers Towards Potential Diagnostic Panels for Lupus. Front Immunol. 2022 Jan 13;12:808839. PMID: 35095896
Ahamada MM, Jia Y, Wu X. Macrophage Polarization and Plasticity in Systemic Lupus Erythematosus. Front Immunol. 2021 Dec 20;12:734008. PMID: 34987500.
